vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and INNO HOLDINGS INC. (INHD). Click either name above to swap in a different company.
Bolt Biotherapeutics, Inc. is the larger business by last-quarter revenue ($2.5M vs $1.5M, roughly 1.7× INNO HOLDINGS INC.). INNO HOLDINGS INC. runs the higher net margin — -2.0% vs -265.2%, a 263.3% gap on every dollar of revenue.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
INNOvative Retail BV, is an upmarket Belgian department store chain that operates sixteen branches around Belgium.
BOLT vs INHD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $1.5M |
| Net Profit | $-6.6M | $-28.6K |
| Gross Margin | — | 5.1% |
| Operating Margin | -283.4% | -33.4% |
| Net Margin | -265.2% | -2.0% |
| Revenue YoY | — | 635.6% |
| Net Profit YoY | 58.4% | 95.3% |
| EPS (diluted) | $-9.38 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $1.5M | ||
| Q3 25 | $2.2M | $1.1M | ||
| Q2 25 | $1.8M | $1.1M | ||
| Q1 25 | $1.2M | $478.1K | ||
| Q4 24 | $0 | $196.0K | ||
| Q3 24 | $1.1M | $490.0K | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.3M | $183.2K |
| Q4 25 | $-6.6M | $-28.6K | ||
| Q3 25 | $-7.1M | $-1.3M | ||
| Q2 25 | $-8.6M | $-1.5M | ||
| Q1 25 | $-11.0M | $-3.6M | ||
| Q4 24 | $-15.9M | $-603.7K | ||
| Q3 24 | $-15.2M | $-287.2K | ||
| Q2 24 | $-21.2M | — | ||
| Q1 24 | $-10.8M | $-1.1M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | -1.5% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.4% | -33.4% | ||
| Q3 25 | -355.1% | -89.7% | ||
| Q2 25 | -510.5% | -143.7% | ||
| Q1 25 | -991.4% | -286.4% | ||
| Q4 24 | — | -233.7% | ||
| Q3 24 | -1441.1% | 87.7% | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | -150.9% |
| Q4 25 | -265.2% | -2.0% | ||
| Q3 25 | -329.4% | -120.5% | ||
| Q2 25 | -474.6% | -142.4% | ||
| Q1 25 | -903.4% | -757.3% | ||
| Q4 24 | — | -308.0% | ||
| Q3 24 | -1330.1% | -58.6% | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | -578.9% |
| Q4 25 | $-9.38 | $-0.01 | ||
| Q3 25 | $-3.72 | $5.03 | ||
| Q2 25 | $-4.46 | $-0.30 | ||
| Q1 25 | $-0.29 | $-0.83 | ||
| Q4 24 | $-13.73 | $-5.21 | ||
| Q3 24 | $-7.93 | $-0.14 | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $37.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $47.2M |
| Total Assets | $56.7M | $47.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $37.1M | ||
| Q3 25 | $31.9M | $10.1M | ||
| Q2 25 | $34.8M | $4.4M | ||
| Q1 25 | $38.8M | $3.9M | ||
| Q4 24 | $47.3M | $4.8M | ||
| Q3 24 | $53.8M | $1.1M | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | $4.0M |
| Q4 25 | $26.5M | $47.2M | ||
| Q3 25 | $32.1M | $15.2M | ||
| Q2 25 | $38.8M | $8.0M | ||
| Q1 25 | $46.8M | $7.1M | ||
| Q4 24 | $57.2M | $9.4M | ||
| Q3 24 | $72.0M | $2.8M | ||
| Q2 24 | $85.9M | — | ||
| Q1 24 | $104.2M | $4.1M |
| Q4 25 | $56.7M | $47.3M | ||
| Q3 25 | $65.1M | $16.0M | ||
| Q2 25 | $75.5M | $8.8M | ||
| Q1 25 | $85.9M | $7.3M | ||
| Q4 24 | $99.6M | $10.7M | ||
| Q3 24 | $109.3M | $4.2M | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $142.9M | $7.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-5.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-5.0M | ||
| Q3 25 | $-9.7M | $-1.0M | ||
| Q2 25 | $-9.6M | $-594.8K | ||
| Q1 25 | $-13.4M | $-1.0M | ||
| Q4 24 | $-14.4M | $-2.1M | ||
| Q3 24 | $-14.0M | $-660.2K | ||
| Q2 24 | $-16.1M | — | ||
| Q1 24 | $-16.8M | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-2.1M | ||
| Q3 24 | $-14.0M | $-795.1K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-3.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -1083.3% | ||
| Q3 24 | -1227.6% | -162.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1720.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 13.7% | ||
| Q3 24 | 3.6% | 27.5% | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | 118.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
